This week, we continue our discussion about metastatic castrate sensitive prostate cancer. Spoiler alert: there is not good guidance or biomarkers that help us pick one regimen over another. In this episode, we go through the data, our critical appraisal of the data, and some things to consider when selecting one regimen over another.
As a refresher, be sure to check out our Pharmacology Episode and our introductory episodes, as we will be building on these concepts.
Content:
- Approach to metastatic disease
- Who needs germline testing?
- History of prostate cancer therapy
- Selecting doublet vs. triplet therapy
** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodes
Love what you hear? Tell a friend and leave a review on our podcast streaming platforms!
Twitter: @TheFellowOnCall
Instagram: @TheFellowOnCall
Listen in on: Apple Podcast, Spotify, and Google Podcast
